B-type Natriuretic Peptide as Predictor of Heart Failure in Patients with Acute ST Elevation Myocardial Infarction, Singlevessel Disease, and Complete Revascularization: Follow-up Study

Manola, Šime; Pavlović, Nikola; Radeljić, Vjekoslav; Delić, Diana; Brkljačić; Pintarić, Hrvoje; Štambuk, Krešimir; Bulj, Nikola; Trbušić, Matias; Krèmar, Tomislav; Lukinac, Ljerka
October 2009
Croatian Medical Journal;Oct2009, Vol. 50 Issue 5, p449
Academic Journal
Aim To assess the concentration of B-type natriuretic peptide (BNP) as a predictor of heart failure in patients with acute ST elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) with successful and complete revascularization. Methods Out of a total of 220 patients with acute STEMI admitted to the Sisters of Mercy University Hospital in the period January 1 to December 31, 2007, only patients with acute STEMI undergoing primary PCI who had single vessel disease and were successfully revascularized were included in the study. Selected patients had no history of myocardial infarction or heart failure and a normal or nearnormal left ventricular ejection fraction (≥50%) assessed by left ventriculography at admission. Only 58 patients met the inclusion criteria for the study. Out of those, 6 patients refused to participate in the study, and another 5 could not be followed up, so a total of 47 patients were evaluated. Blood samples were taken for measurement of BNP levels at admission, 24 hours later, and 7 days later. Patients were followed up for 1 year. The primary outcome was reduction in left ventricular ejection fraction (LVEF) to <50% after 1 year. Results Patients who developed echocardiographic signs of reduced systolic function defined as LVEF<50% had significantly higher values of BNP (≥80 pg/mL) at 24 hours (P = 0.001) and 7 days (P = 0.020) after STEMI and successful reperfusion. Patients who had BNP levels ≥80 pg/mL after 7 days were 21 times more likely to develop LVEF<50 (odds ratio, 20.8; 95% confidence interval, 2.2-195.2; P = 0.008). Conclusion BNP can be used as a predictor of reduced systolic function in patients with STEMI who underwent successful reperfusion and had normal ejection fraction at admission.


Related Articles

  • Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Libetta, Carmelo; Sepe, Vincenzo; Zucchi, Manuela; Pisacco, Patrizia; Cosmai, Laura; Meloni, Federica; Campana, Carlo; Rampino, Teresa; Monti, Cristina; Tavazzi, Luigi; Canton, Antonio Dal // Nephrology Dialysis Transplantation;Jul2007, Vol. 22 Issue 7, p2013 

    Background. Elevated plasma levels of cytokines have been associated with an increased risk of congestive heart failure (CHF) even in people without history of myocardial infarction. Here we have tested the hypothesis that effective removal of pro-inflammatory cytokines in patients with advanced...

  • B-Type Natriuretic Peptide (BNP) and Left Ventricular (LV) Function in Patients with ST-Segment Elevation Myocardial Infarction (STEMI). Dorobantu, Maria; Fruntelata, Ana-Gabriela; Scafa-Udriste, Alexandru; Tautu, Oana-Florentina // Maedica - a Journal of Clinical Medicine;2010, Vol. 5 Issue 4, p243 

    Background: After acute myocardial infarction (AMI), left ventricular (LV) function is a well-established prognostic marker. Recent studies indicate that serum levels of brain natriuretic peptide (BNP) also represent an prognostic marker in this setting but so far without a precise cut-off...

  • Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Tentzeris, Ioannis; Jarai, Rudolf; Farhan, Serdar; Perkmann, Thomas; Schwarz, Michael A.; Jakl, Gabriele; Wojta, Johann; Huber, Kurt // European Journal of Heart Failure;Jul2011, Vol. 13 Issue 7, p726 

    Aims Copeptin, the C-terminal part of the vasopressin pro-hormone, is elevated after myocardial infarction and predicts adverse outcome. In the present study we investigated whether the complementary role of copeptin and cardiac troponin T (cTnT) could be used for identification of high-risk...

  • 316. Increased renal neutral endopeptidase activity may be a factor in CHF progression. Knecht, M.; Pagel, I.; Langenickel, T. // Kidney;May/Jun2003, Vol. 12 Issue 3, p110 

    Objective: To elucidate the loss of natriuretic and diuretic properties of atrial natriuretic peptide (ANP) in congestive heart failure (CHF). Methodology: Activity, protein concentrations, mRNA, and immunostaining of neutral endopeptidase (NEP) in kidneys of different models of severe CHF in...

  • Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Chen, H. H.; Martin, F. L.; Gibbons, R. J.; Schirger, J. A.; Wright, R. S.; Schears, R. M.; Redfield, M. M.; Simari, R. D.; Lerman, A.; Cataliotti, A.; Burnett Jr, J. C. // Heart;Aug2009, Vol. 95 Issue 16, p11 

    Background: B-type natriuretic peptide (BNP, nesiritide) has anti-fibrotic, anti-hypertrophic, anti-inflammatory, vasodilating, lusitropic and aldosterone-inhibiting properties but conventional doses of BNP cause hypotension, limiting its use in heart failure. Objective: To determine whether...

  • Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Yoshimura, Michihiro; Yasue, Hirofumi; Ogawa, Hisao // Canadian Journal of Physiology & Pharmacology;Aug2001, Vol. 79 Issue 8, p730 

    Plasma levels of ANP and BNP increase in accordance with the severity of the heart failure. In severe cases, the amount of BNP secreted surpasses that of ANP. The main secretion site of BNP is the ventricles, and that of ANP is the atria. However, ANP is also secreted from the ventricles as...

  • MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Tzikas, Stergios; Keller, Till; Ojeda, Francisco M.; Zeller, Tanja; Wild, Philipp S.; Lubos, Edith; Kunde, Jan; Baldus, Stephan; Bickel, Christoph; Lackner, Karl J.; Münzel, Thomas F.; Blankenberg, Stefan // Heart;Mar2013, Vol. 99 Issue 6, p388 

    Objective: To evaluate mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) as prognostic biomarkers in a representative 'real world' cohort of patients with suspected acute coronary syndrome (ACS). Design: Prospective observational multicentre...

  • Natriuretic peptides in acute myocardial infarction. Ribeiro, Antonio Luiz P. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/16/2009, Vol. 338 Issue 7704, p1154 

    The author reflects on the therapeutic value of N-terminal fragment of B type natriuretic peptide (BNP) prohormone (NT-ProBNP) for acute myocardial infarction based on a cohort study of 3291 elderly patients. He says that the role of BNP an NT-ProBNP has been studied more thoroughly in the case...

  • Cohort study of plasma natriuretic peptides for identiying left ventricular systolic dysfunction... McClure, Samuel J.; Caruana, Lynn // BMJ: British Medical Journal (International Edition);08/22/98, Vol. 317 Issue 7157, p516 

    Presents information on the results of a study which was conducted to determine whether blood natriuretic peptide concentrations are helpful in identifying or excluding left ventricular systolic dysfunction, in stable survivors of acture myocardial infraction. Number of people that participated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics